OBJECTIVE: To compare survival times of HIV-1 single and HIV-1 and HIV-2 dual-infected individuals. DESIGN: Prospective open cohort study. METHODS: We analysed data from 259 HIV-1-seroincident cases (either HIV-1 single or HIV-1 and HIV-2 dual-infected) from a cohort with long follow-up (~20 years) in order to study the influence of type of infection and infection order on mortality. Sex and age at HIV-1 infection date was controlled for in a Cox proportional-hazards model. RESULTS: Dual-infected individuals had a 42% longer time from HIV-1 infection to death compared with single-infected individuals, adjusting for age asymmetries between groups. Dual-infected individuals with an HIV-2 infection preceding the HIV-1 infection had a more than two-fold lower mortality risk during follow-up than HIV-1 single-infected individuals. CONCLUSION: Survival time is longer and the risk of progression to death is lower among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals. This natural inhibition could have implications for the development of future HIV-1 vaccines and therapeutics.
OBJECTIVE: To compare survival times of HIV-1 single and HIV-1 and HIV-2 dual-infected individuals. DESIGN: Prospective open cohort study. METHODS: We analysed data from 259 HIV-1-seroincident cases (either HIV-1 single or HIV-1 and HIV-2 dual-infected) from a cohort with long follow-up (~20 years) in order to study the influence of type of infection and infection order on mortality. Sex and age at HIV-1 infection date was controlled for in a Cox proportional-hazards model. RESULTS: Dual-infected individuals had a 42% longer time from HIV-1 infection to death compared with single-infected individuals, adjusting for age asymmetries between groups. Dual-infected individuals with an HIV-2 infection preceding the HIV-1 infection had a more than two-fold lower mortality risk during follow-up than HIV-1 single-infected individuals. CONCLUSION: Survival time is longer and the risk of progression to death is lower among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals. This natural inhibition could have implications for the development of future HIV-1 vaccines and therapeutics.
Authors: Sanne Jespersen; Bo Langhoff Hønge; Candida Medina; David da Silva Té; Faustino Gomes Correira; Alex Lund Laursen; Christian Erikstrup; Lars Østergaard; Christian Wejse Journal: J Int AIDS Soc Date: 2015-09-29 Impact factor: 5.396
Authors: Susanna M Bächle; David F G Malone; Marcus Buggert; Annika C Karlsson; Per-Erik Isberg; Antonio J Biague; Hans Norrgren; Patrik Medstrand; Markus Moll; Johan K Sandberg; Marianne Jansson Journal: AIDS Date: 2016-07-17 Impact factor: 4.177
Authors: Joakim Esbjörnsson; Patrik Medstrand; Angelica A Palm; Philippe Lemey; Marianne Jansson; Fredrik Månsson; Anders Kvist; Zsófia Szojka; Antonio Biague; Zacarias José da Silva; Sarah L Rowland-Jones; Hans Norrgren Journal: mBio Date: 2019-01-08 Impact factor: 7.867
Authors: Joakim Esbjörnsson; Marianne Jansson; Sanne Jespersen; Fredrik Månsson; Bo L Hønge; Jacob Lindman; Candida Medina; Zacarias J da Silva; Hans Norrgren; Patrik Medstrand; Sarah L Rowland-Jones; Christian Wejse Journal: AIDS Res Ther Date: 2019-09-05 Impact factor: 2.250
Authors: Lydia Scharf; Christina B Pedersen; Emil Johansson; Jacob Lindman; Lars R Olsen; Marcus Buggert; Sten Wilhelmson; Fredrik Månsson; Joakim Esbjörnsson; Antonio Biague; Patrik Medstrand; Hans Norrgren; Annika C Karlsson; Marianne Jansson Journal: Front Immunol Date: 2021-10-12 Impact factor: 7.561
Authors: Emil Johansson; Priscilla F Kerkman; Lydia Scharf; Jacob Lindman; Zsófia I Szojka; Fredrik Månsson; Antonio Biague; Patrik Medstrand; Hans Norrgren; Marcus Buggert; Annika C Karlsson; Mattias N E Forsell; Joakim Esbjörnsson; Marianne Jansson Journal: Cells Date: 2022-10-06 Impact factor: 7.666
Authors: Marcus Buggert; Juliet Frederiksen; Ole Lund; Michael R Betts; Antonio Biague; Morten Nielsen; Johanna Tauriainen; Hans Norrgren; Patrik Medstrand; Annika C Karlsson; Marianne Jansson Journal: AIDS Date: 2016-10-23 Impact factor: 4.177
Authors: S Jespersen; F Månsson; J Lindman; C Wejse; C Medina; Z J da Silva; DdS Te; P Medstrand; J Esbjörnsson; B L Hønge Journal: AIDS Res Ther Date: 2020-02-04 Impact factor: 2.250